ClinicalTrials.gg
CompletedNCT04162769ADVISEUpdated Nov 4, 2022Results posted

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

A Phase 2 interventional study of Etrasimod 1 mg and Etrasimod 2 mg in Atopic Dermatitis, sponsored by Arena Pharmaceuticals. Completed at 38 sites in 3 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-04.

Sponsored by Arena Pharmaceuticals (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
22nd of 47
140 · median 121
Started
2019
with 7 others
Phase 2
13 of 58
1 open now
Registered
28th of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 22nd largest by enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2019, is one of 13 in phase 2, and was the 28th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Moderate-to-severe atopic dermatitis
  • Etrasimod
  • APD334
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with chronic atopic dermatitis, defined by Hanifin and Rajka criteria, that has been present for at least 1 year prior to the Screening Visit
  • Participants with Eczema Area and Severity Index (EASI) ≥ 12 at the Screening Visit and ≥ 16 at the Baseline Visit
  • Participants with validated Investigator's Global Assessment (vIGA) score ≥ 3 (on the 0 to 4 vIGA scale, in which 3 = moderate and 4 = severe) involvement at the Screening and Baseline visits

Exclusion criteria

Exclusion Criteria:

  • Presence of skin comorbidities that would interfere with study assessments of the underlying disease.
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
140 participants (actual)

Study arms

  • Experimental
    12-Week Double-Blind Treatment Period: Etrasimod 1 milligrams (mg)

    Drug: Etrasimod 1 mg

  • Experimental
    12-Week Double-Blind Treatment Period: Etrasimod 2 mg

    Drug: Etrasimod 2 mg

  • Placebo comparator
    12-Week Double-Blind Treatment Period: Placebo

    Drug: Etrasimod matching placebo

  • Experimental
    52-Week Open-Label Extension Period: Etrasimod 2 mg

    Drug: Etrasimod 2 mg

Interventions

  • Etrasimod 1 mg tablet taken by mouth, once daily

    Also known as: APD334

  • Etrasimod 2 mg tablet taken by mouth, once daily.

    Also known as: APD334

  • DrugEtrasimod matching placebo

    Etrasimod matching placebo tablet by mouth, once daily.

06

What researchers measure

Primary outcomes

  1. Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score

    EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

Secondary outcomes

  1. Double-blind Treatment Period: Percentage of Participants Achieving EASI-75

    EASI-75 is defined as a 75% reduction or greater in EASI score from Baseline to Week 12. Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

  2. Double-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points

    The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

  3. Double-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary

    Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

  4. Double-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary

    Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Percentage of participants with improvement (reduction) in peak pruritus NRS \>=3 from an itch daily diary is presented. Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

  5. Double-blind Treatment Period: Percentage of Participants Achieving EASI-50

    EASI-50 is defined as a 50% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-50 is presented. Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

  6. Double-blind Treatment Period: Percentage of Participants Achieving EASI-90

    EASI-90 is defined as as a 90% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-90 is presented Baseline is defined as Day 1 pre-randomization assessments.

    Time frame: Baseline (Day 1) and Week 12

  7. Double-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA)

    BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments

    Time frame: Baseline (Day 1) and Week 12

  8. Open-label Extension (OLE) Period: Percent Change in EASI

    EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

    Time frame: Baseline (Week 16) and Week 68

  9. OLE Period: Number of Participants Achieving a EASI-75 Score

    EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. EASI-75 is defined as a \>=75% reduction or greater of EASI from Baseline.

    Time frame: Baseline (Week 16) and Week 68

  10. OLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of ≥ 2 Points

    The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity.

    Time frame: Baseline (Week 16) and Week 68

  11. OLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score

    The SCORAD is a validated measure of the extent and severity of AD using 3 components: A = extent or affected BSA, B = severity and C = subjective symptoms. The extent of AD was assessed as percentage of each defined body area and reported as the sum of all areas, with a maximum score of 100%. The severity of 6 specific symptoms was assessed using the following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points, assigned as "B" in the overall SCORAD calculation). Subjective assessment of itch and sleeplessness was recorded for each symptom by the participant or relative on a Visual Analogue Scale, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum possible score of 20. This parameter is assigned as "C" in the overall SCORAD calculation. The total SCORAD ranged from 0 (no disease) to 103 (severe disease); higher score indicated more severe AD.

    Time frame: Baseline (Week 16) and Week 68

  12. OLE Period: Percent Change in Percent BSA

    BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

    Time frame: Baseline (Week 16) and Week 68

  13. OLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary

    Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

    Time frame: Baseline (Week 16) and Week 28

  14. OLE Period: Change in Patient-Oriented Eczema Measure (POEM)

    The POEM is a participant-derived validated tool used for monitoring atopic eczema severity. The POEM consisted of 7 questions asking participants to rank how many days over the past 7 days they had experienced specific AD-related symptoms. Each of the 7 questions carried equal weight and was scored from 0 to 4 as follows: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; Every day = 4. The scores from the 7 questions were added up to give an overall POEM score as: 0-2 = 'clear/almost clear', 3-7 = 'mild', 8-16 = 'moderate', 17-24 = 'severe', and 25-28 = 'very severe atopic eczema'; higher scores indicated worse atopic eczema severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

    Time frame: Baseline (Week 16) and Week 68

  15. OLE Period: Change in Dermatology Life Quality Index (DLQI)

    The DLQI is a validated 10-item questionnaire designed to measure the impact of skin disease on the Quality of Life (QoL). DLQI is a response to 10 items, which assessed QoL over the past week. For each item, the scale was rated as follows: 0 = "not at all"; 1 = "a little"; 2 = "a lot"; 3 = "very much," with an overall scoring system of 0 to 30; higher scores indicated a poor QoL. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

    Time frame: Baseline (Week 16) and Week 68

  16. OLE Period: Change in Patient Global Assessment (PGA) of Disease

    PGA is an assessment tool that was used by participant to rate the disease and disease severity. Participants rated their overall well-being based on a 5-point Likert scale from poor to excellent. Response choices were: 1- 'Poor', 2- 'Fair', 3- 'Good', 4- 'Very Good,' or 5- 'Excellent'; higher scores indicated better well-being. For the 5-point Likert scale, a positive change from baseline indicates an improvement. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

    Time frame: Baseline (Week 16) and Week 68

07

Results

Posted Nov 4, 2022

Participant flow

This was a 2-treatment period study (12-Week Double-Blind Treatment Period and 52-Week Open-label extension \[OLE\] Period), to evaluate the safety and efficacy of etrasimod monotherapy compared with placebo in participants with moderate-to-severe atopic dermatitis (AD), whose disease was not adequately controlled with topical therapies.

Double-blind Treatment (12-Week)
Participant flow — Double-blind Treatment (12-Week)
MilestoneDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboOLE Period: Etrasimod 2 mg
Started4747460
Completed3436370
Not completed131190
Withdrew: Adverse event2500
Withdrew: Withdrawal by subject4320
Withdrew: Physician decision1000
Withdrew: Lost to follow-up5160
Withdrew: Protocol deviation1100
Withdrew: Other0110
OLE Period (52-Week)
Participant flow — OLE Period (52-Week)
MilestoneDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboOLE Period: Etrasimod 2 mg
Started00095
Completed00068
Not completed00027
Withdrew: Adverse event0005
Withdrew: Withdrawal by subject00010
Withdrew: Physician decision0001
Withdrew: Lost to follow-up0009
Withdrew: Protocol deviation0002

Outcome measures

PrimaryDouble-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score

EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · Percent change
Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score
Percent changeDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percent Change in Eczema Area and Severity Index (EASI) Score-58.68 ± 7.735-57.18 ± 7.800-48.41 ± 8.378
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · ANCOVA · p = =0.1198 · Least square mean difference: -10.28 · 95% CI -23.228 to 2.674
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · ANCOVA · p = =0.1783 · Least square mean difference: -8.77 · 95% CI -21.544 to 4.002
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving EASI-75

EASI-75 is defined as a 75% reduction or greater in EASI score from Baseline to Week 12. Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving EASI-75
Percentage of participantsDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percentage of Participants Achieving EASI-7527.7 (15.62 to 42.64)38.3 (24.51 to 53.62)26.1 (14.27 to 41.13)
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.9826 · Response rate difference: -0.2 · 95% CI -18.52 to 18.11
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.1891 · Response rate difference: 13.0 · 95% CI -6.12 to 32.21
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points

The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points
Percentage of participantsDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percentage of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of >= 2 Points14.9 (6.20 to 28.31)29.8 (17.34 to 44.89)13.0 (4.94 to 26.26)
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.7694 · Response rate difference: 2.2 · 95% CI -12.29 to 16.64
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.0450 · Response rate difference: 17.4 · 95% CI 0.79 to 34.00
SecondaryDouble-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary

Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · Percent change
Double-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary
Percent changeDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percent Change in Weekly Peak Pruritus Numerical Rating Scale (NRS) From an Itch Daily Diary-38.401 ± 8.236-35.044 ± 7.910-24.374 ± 8.492
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Mixed Models Analysis · p = =0.0558 · Least square mean difference: -14.03 · 95% CI -28.406 to 0.352
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Mixed Models Analysis · p = =0.1363 · Least square mean difference: -10.67 · 95% CI -24.737 to 3.397
SecondaryDouble-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary

Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Percentage of participants with improvement (reduction) in peak pruritus NRS \>=3 from an itch daily diary is presented. Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Double-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary
Percentage of participantsDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percentage of Participants With Improvement (Reduction) in Peak Pruritus NRS Greater Than or Equal to (>=)3 From an Itch Daily Diary45.0 (29.26 to 61.51)45.0 (29.26 to 61.51)41.0 (25.57 to 57.90)
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.7143 · Response rate difference: 4.2 · 95% CI -18.00 to 26.41
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.6488 · Response rate difference: 5.1 · 95% CI -16.62 to 26.87
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving EASI-50

EASI-50 is defined as a 50% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-50 is presented. Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving EASI-50
Percentage of participantsDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percentage of Participants Achieving EASI-5061.7 (46.38 to 75.49)66.0 (50.69 to 79.14)52.2 (36.95 to 67.11)
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.3981 · Response rate difference: 8.8 · 95% CI -11.27 to 28.80
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.1410 · Response rate difference: 15.2 · 95% CI -4.72 to 35.15
SecondaryDouble-blind Treatment Period: Percentage of Participants Achieving EASI-90

EASI-90 is defined as as a 90% reduction or greater of EASI from Baseline to Week 12. Percentage of participants achieving EASI-90 is presented Baseline is defined as Day 1 pre-randomization assessments.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Double-blind Treatment Period: Percentage of Participants Achieving EASI-90
Percentage of participantsDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percentage of Participants Achieving EASI-9019.1 (9.15 to 33.26)14.9 (6.20 to 28.31)10.9 (3.62 to 23.57)
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.2690 · Response rate difference: 8.4 · 95% CI -6.61 to 23.38
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Cochran-Mantel-Haenszel · p = =0.5428 · Response rate difference: 4.3 · 95% CI -9.56 to 18.25
SecondaryDouble-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA)

BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as Day 1 pre-randomization assessments

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Least squares mean · Percent change
Double-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA)
Percent changeDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: Placebo
Double-blind Treatment Period: Percent Change in Percent Body Surface Area (BSA)-34.725 ± 7.047-45.153 ± 6.860-31.913 ± 7.012
Statistical analysis
  • Double-blind Treatment Period: Etrasimod 1 Milligrams (mg) vs Double-blind Treatment Period: Placebo · Mixed Models Analysis · p = =0.7163 · Least square mean difference: -2.81 · 95% CI -18.089 to 12.466
  • Double-blind Treatment Period: Etrasimod 2 mg vs Double-blind Treatment Period: Placebo · Mixed Models Analysis · p = =0.0840 · Least square mean difference: -13.24 · 95% CI -28.284 to 1.805
SecondaryOpen-label Extension (OLE) Period: Percent Change in EASI

EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Mean · Percent change
Open-label Extension (OLE) Period: Percent Change in EASI
Percent changeOLE Period: Etrasimod 2 mg
Open-label Extension (OLE) Period: Percent Change in EASI-45.39 ± 258.796
SecondaryOLE Period: Number of Participants Achieving a EASI-75 Score

EASI evaluates severity of participant's AD based on severity of AD clinical signs and percent (%) of body surface area (BSA) affected. EASI is a composite scoring assessment of the affected area in 4 specific disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification), which was each assessed on a scale of "0" (absent) through "3" (severe). The EASI Area Score is documented for 4 regions of the body. Region 1: head and neck; Region 2: trunk (including genital area); Region 3: upper limbs; and Region 4: lower limbs (including buttocks), with the area of AD involvement assessed as a percentage by body area and converted to a score of 0 to 6. Total EASI score ranged from 0 to 72; higher score indicated greater severity of AD. EASI-75 is defined as a \>=75% reduction or greater of EASI from Baseline.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Count of participants · Participants
OLE Period: Number of Participants Achieving a EASI-75 Score
ParticipantsOLE Period: Etrasimod 2 mg
OLE Period: Number of Participants Achieving a EASI-75 Score65
SecondaryOLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of ≥ 2 Points

The vIGA scale for AD is a 5-point scale to measure disease severity. The vIGA score was selected using descriptors that best described the overall appearance of skin lesions at a given time point using the following scoring: 0 = clear (no inflammatory signs of AD); 1 = almost clear (barely perceptible erythema and papulation); 2 = mild (slight but definite erythema and papulation); 3 = moderate (clearly perceptible erythema and papulation); and 4 = severe (marked erythema and papulation); Higher score indicated greater severity.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Count of participants · Participants
OLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of ≥ 2 Points
ParticipantsOLE Period: Etrasimod 2 mg
OLE Period: Number of Participants Achieving a Validated Investigator Global Assessment (vIGA) 0 or 1 Score and a Reduction From Baseline of ≥ 2 Points31
SecondaryOLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score

The SCORAD is a validated measure of the extent and severity of AD using 3 components: A = extent or affected BSA, B = severity and C = subjective symptoms. The extent of AD was assessed as percentage of each defined body area and reported as the sum of all areas, with a maximum score of 100%. The severity of 6 specific symptoms was assessed using the following scale: none (0), mild (1), moderate (2), or severe (3) (for a maximum of 18 total points, assigned as "B" in the overall SCORAD calculation). Subjective assessment of itch and sleeplessness was recorded for each symptom by the participant or relative on a Visual Analogue Scale, where 0 is no itch (or sleeplessness) and 10 is the worst imaginable itch (or sleeplessness), with a maximum possible score of 20. This parameter is assigned as "C" in the overall SCORAD calculation. The total SCORAD ranged from 0 (no disease) to 103 (severe disease); higher score indicated more severe AD.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Mean · Percent change
OLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score
Percent changeOLE Period: Etrasimod 2 mg
OLE Period: Percent Change in SCORing Atopic Dermatitis (SCORAD) Total Score-64.27 ± 69.273
SecondaryOLE Period: Percent Change in Percent BSA

BSA affected by AD were assessed for each section of the body. The possible highest score for each region was: head and neck (9%), anterior trunk (18%), back (18%), upper limbs (18%), lower limbs (36%), and genitals (1%) and were reported as a percentage of all major body sections combined; higher % BSA indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Mean · Percent change
OLE Period: Percent Change in Percent BSA
Percent changeOLE Period: Etrasimod 2 mg
OLE Period: Percent Change in Percent BSA-68.47 ± 52.083
SecondaryOLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary

Pruritus NRS is an assessment tool that was used to report the intensity of a participant's pruritus (itch). The scale for the pruritus NRS ranged from 0 to 10 with 0 being "no itch" and 10 being "the worst itch imaginable; higher scores indicated greater severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

Time frame:
Baseline (Week 16) and Week 28
Reported as:
Mean · Percent change
OLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary
Percent changeOLE Period: Etrasimod 2 mg
OLE Period: Percent Change in Weekly Peak Pruritus NRS From an Itch Daily Diary-36.87 ± 45.219
SecondaryOLE Period: Change in Patient-Oriented Eczema Measure (POEM)

The POEM is a participant-derived validated tool used for monitoring atopic eczema severity. The POEM consisted of 7 questions asking participants to rank how many days over the past 7 days they had experienced specific AD-related symptoms. Each of the 7 questions carried equal weight and was scored from 0 to 4 as follows: No days = 0; 1-2 days = 1; 3-4 days = 2; 5-6 days = 3; Every day = 4. The scores from the 7 questions were added up to give an overall POEM score as: 0-2 = 'clear/almost clear', 3-7 = 'mild', 8-16 = 'moderate', 17-24 = 'severe', and 25-28 = 'very severe atopic eczema'; higher scores indicated worse atopic eczema severity. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Mean · Scores on a scale
OLE Period: Change in Patient-Oriented Eczema Measure (POEM)
Scores on a scaleOLE Period: Etrasimod 2 mg
OLE Period: Change in Patient-Oriented Eczema Measure (POEM)-6.3 ± 6.50
SecondaryOLE Period: Change in Dermatology Life Quality Index (DLQI)

The DLQI is a validated 10-item questionnaire designed to measure the impact of skin disease on the Quality of Life (QoL). DLQI is a response to 10 items, which assessed QoL over the past week. For each item, the scale was rated as follows: 0 = "not at all"; 1 = "a little"; 2 = "a lot"; 3 = "very much," with an overall scoring system of 0 to 30; higher scores indicated a poor QoL. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Mean · Scores on a scale
OLE Period: Change in Dermatology Life Quality Index (DLQI)
Scores on a scaleOLE Period: Etrasimod 2 mg
OLE Period: Change in Dermatology Life Quality Index (DLQI)-5.4 ± 6.03
SecondaryOLE Period: Change in Patient Global Assessment (PGA) of Disease

PGA is an assessment tool that was used by participant to rate the disease and disease severity. Participants rated their overall well-being based on a 5-point Likert scale from poor to excellent. Response choices were: 1- 'Poor', 2- 'Fair', 3- 'Good', 4- 'Very Good,' or 5- 'Excellent'; higher scores indicated better well-being. For the 5-point Likert scale, a positive change from baseline indicates an improvement. Baseline is defined as the last measurement prior to the first etrasimod dose started at Week 16.

Time frame:
Baseline (Week 16) and Week 68
Reported as:
Mean · Scores on a scale
OLE Period: Change in Patient Global Assessment (PGA) of Disease
Scores on a scaleOLE Period: Etrasimod 2 mg
OLE Period: Change in Patient Global Assessment (PGA) of Disease1.23 ± 1.209

Adverse events

Collected over All-cause mortality, TEAEs and SAEs were collected for Double-blind Treatment period (12-Week) and for OLE Period (52-Week).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Treatment Period: Etrasimod 1 Milligrams (mg)0/47 (0%)0/47 (0%)19/47 (40.4%)
Double-blind Treatment Period: Etrasimod 2 mg0/47 (0%)0/47 (0%)31/47 (66%)
Double-blind Treatment Period: Placebo0/46 (0%)0/46 (0%)22/46 (47.8%)
OLE Period: Etrasimod 2 mg0/95 (0%)3/95 (3.2%)53/95 (55.8%)
Most frequent serious events
Most frequent serious events
EventDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboOLE Period: Etrasimod 2 mg
Extradural abscessInfections and infestations0/470/470/461/95
Staphylococcal bacteraemiaInfections and infestations0/470/470/461/95
Tooth abscessInfections and infestations0/470/470/461/95
PneumoniaInfections and infestations0/470/470/461/95
SepsisInfections and infestations0/470/470/461/95
Arthropod biteInjury, poisoning and procedural complications0/470/470/461/95
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/470/470/461/95
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/470/470/461/95
Most frequent other events
Showing 10 of 143
Most frequent other events
EventDouble-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboOLE Period: Etrasimod 2 mg
Lymphocyte count decreasedInvestigations1/477/470/467/95
HeadacheNervous system disorders1/470/474/465/95
Dermatitis atopicSkin and subcutaneous tissue disorders0/472/474/465/95
Urinary tract infectionInfections and infestations0/473/473/463/95
ConstipationGastrointestinal disorders0/473/470/461/95
NauseaGastrointestinal disorders1/473/472/464/95
Back painMusculoskeletal and connective tissue disorders0/473/471/462/95
DizzinessNervous system disorders2/473/471/464/95
SARS-CoV-2 test positiveInvestigations0/470/470/465/95
Herpes zosterInfections and infestations0/470/472/460/95

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants, irrespective of whether they received any study intervention.

Age, Continuous
Age, Continuous(Years)Double-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboTotal
Mean41.7 ± 13.3241.8 ± 14.8344.1 ± 16.1642.5 ± 14.74
Sex: Female, Male
Sex: Female, Male(Participants)Double-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboTotal
Female30282785
Male17191955
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-blind Treatment Period: Etrasimod 1 Milligrams (mg)Double-blind Treatment Period: Etrasimod 2 mgDouble-blind Treatment Period: PlaceboTotal
White27263184
Asian2327
Black or African American15181144
American Indian or Alaska Native2013
Native Hawaiian or other Pacific Islander1001
Other0011
08

Study locations

38 sites
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Hope Clinical Research
    Canoga Park, California 91303, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Marvel Research LLC
    Huntington Beach, California 92647, United States
  • ADVA Clinical Research, Inc
    Inglewood, California 90301, United States
  • Providence Clinical Research
    North Hollywood, California 91606, United States
  • TCR Medical Corporation
    San Diego, California 92123, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Prohealth Research Center
    Doral, Florida 33166, United States
  • Aby's New Generation Research, Inc.
    Hialeah, Florida 33016, United States
  • Skin Care Research, LLC
    Hollywood, Florida 33021, United States
  • Advanced Research Institute of Miami LLC
    Homestead, Florida 33030, United States
  • Amber Pediatrics Research, LLC
    Homestead, Florida 33030, United States
  • Amber Clinical Research, LLC
    Miami Shores, Florida 33138, United States
  • South Miami Medical & Research Group. Inc
    Miami, Florida 33155, United States
  • Amber Pediatrics Research, LLC
    Miami, Florida 33169, United States
  • Skin Research of South Florida
    Miami, Florida 33173, United States
  • IMA Clinical Research, LLC
    Saint Petersburg, Florida 33709, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • Rophe Adult and Pediatric Medicine/SKYCRNG
    Union City, Georgia 30291, United States
  • Skin Sciences PLLC
    Louisville, Kentucky 40217, United States
  • Quinn Healthcare/SKYCRNG
    Ridgeland, Mississippi 39157, United States
  • Quality Clinical Research Inc
    Omaha, Nebraska 68114, United States
  • Excel Clinical Research
    Las Vegas, Nevada 89109, United States
  • Greenwich Village Dermatology
    New York, New York 10012, United States
  • ODRC Enterprises, LLC dba Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Spartanburg Medical Research
    Spartanburg, South Carolina 29369, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Gadolin Research
    Beaumont, Texas 77702, United States
  • Modern Research Associates, PLLC
    Dallas, Texas 75231, United States
  • FMC Science
    Georgetown, Texas 78626, United States
  • FMC Science
    Lampasas, Texas 76550, United States
  • Alliance for Multispecialty Research
    Norfolk, Virginia 23507, United States
  • Clinical Research Partners, LLC
    Richmond, Virginia 23220, United States
  • Premier Clinical Research
    Spokane, Washington 99202, United States
  • Premier Specialists PTY LTD
    Kogarah, New South Wales 2217, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Diex Recherche Sherbrooke Inc.
    Sherbrooke, Quebec J1L 0H8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Sep 2020, 11 months.

Results were first posted in Nov 2022, 2 years 1 month after primary completion. A results delay was requested in Sep 2021.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 11 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 14, 2019
StartActual
Oct 4, 2019
Primary completionActual
Sep 9, 2020
CompletionActual
Oct 11, 2021
Results delay requested
Sep 13, 2021
Results first posted
Nov 4, 2022
Last update
Nov 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04162769
Responsible party
Sponsor
First posted
Nov 14, 2019
Start date
Oct 4, 2019
Primary completion
Sep 9, 2020
Completion
Oct 11, 2021
Results posted
Nov 4, 2022
Last update
Nov 4, 2022

Study contacts

Arena CT.gov Administrator
study director · Arena Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etrasimod

Start the discussion